$XNCR News

Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat

Xencor Reports First Quarter 2026 Financial Results

Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 - Slideshow

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

JP Morgan Downgrades Xencor to Neutral, Lowers Price Target to $13

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor shares are trading lower after Alexion Pharmaceuticals informed the company it does not owe additional royalties for Ultomiris sales in the U.S.

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor Announces That Alexion Pharmaceuticals Informed Xencor That It Has Taken The Position That The Licensee Does Not Owe Any Additional Royalties For Sales Of Ultomiris In The United States And That The Licensee Does Not Intend To Make Any Future Payments For Sales In The United States

Barclays Maintains Overweight on Xencor, Raises Price Target to $27

Xencor shares are trading higher after the company reported better-than-expected Q4 EPS results.

Xencor: Q4 Earnings Snapshot

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor Q4 EPS $(0.09) Beats $(0.54) Estimate, Sales $28.200M Miss $31.686M Estimate

Xencor to Participate at Upcoming Investor Conferences

What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector